Literature DB >> 28879245

Effects of High-Dose Capsaicin on TMD Subjects: A Randomized Clinical Study.

B K Campbell1, R B Fillingim2, S Lee3, R Brao4, D D Price5, J K Neubert4.   

Abstract

Temporomandibular joint disorder (TMD) is a complex musculoskeletal disorder that presents with pain, limited jaw opening, and abnormal noises in the temporomandibular joint. Despite the significant impact that TMD has in terms of suffering and financial burden, relatively few new treatments have emerged; therefore, development of novel treatments to treat TMD pain remains a high priority. The rationale of this study was to use a double-blind, vehicle-controlled clinical trial to evaluate the effects of a high-concentration (8%) capsaicin cream on TMD. This is based on the hypothesis that targeting TRP vanilloid subfamily member 1 (TRPV1) for pain control may provide a novel method for pain relief in TMD patients. TRPV1 is primarily expressed on a population of nociceptive-specific neurons and provides a candidate target for the development of pain treatments. Capsaicin is the primary agonist for TRPV1 and has been used previously in relatively low doses (0.025% to 0.075%) as a therapeutic for a variety of pain disorders, including postherpetic neuralgia and osteoarthritis; however, analgesic efficacy remains equivocal. TMD and healthy control subjects were assigned to either an active capsaicin or vehicle control group. The treatments were applied for 2 h and then removed. Quantitative sensory testing (QST) was completed prior to drug application (baseline), 2 h after drug application, and 1 wk later. Perceived pain intensity was measured using a visual analog scale (VAS) following capsaicin or vehicle cream application. Significantly lower pain was reported in the week after application in the capsaicin-treated TMD subjects. For QST measures, there was a decreased thermal pain threshold 2 h after capsaicin application for both the control and TMD groups, but this resolved within a week. Capsaicin had no effect on pressure pain threshold or mechanical sensitivity in both TMD and healthy individuals. This study demonstrates that 8% topical capsaicin therapy is a relatively safe, simple, and effective treatment for patients with TMD. Knowledge Transfer Statement: This study evaluated a novel topical capsaicin therapy for reducing orofacial pain. The results of this study can be used to provide another treatment option for patients with TMD.

Entities:  

Keywords:  TRPV1; clinical study; neuropharmacology; neuroscience/neurobiology; orofacial pain; pain

Year:  2016        PMID: 28879245      PMCID: PMC5576044          DOI: 10.1177/2380084416675837

Source DB:  PubMed          Journal:  JDR Clin Trans Res        ISSN: 2380-0844


  29 in total

Review 1.  The vanilloid receptor: a molecular gateway to the pain pathway.

Authors:  M J Caterina; D Julius
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

Review 2.  The whole body receptive field of dorsal horn multireceptive neurones.

Authors:  Daniel Le Bars
Journal:  Brain Res Brain Res Rev       Date:  2002-10

Review 3.  Lessons from peppers and peppermint: the molecular logic of thermosensation.

Authors:  Sven-Eric Jordt; David D McKemy; David Julius
Journal:  Curr Opin Neurobiol       Date:  2003-08       Impact factor: 6.627

Review 4.  Vanilloid receptor TRPV1 antagonists as the next generation of painkillers. Are we putting the cart before the horse?

Authors:  Arpad Szallasi; Giovanni Appendino
Journal:  J Med Chem       Date:  2004-05-20       Impact factor: 7.446

5.  Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation.

Authors:  M Nolano; D A Simone; G Wendelschafer-Crabb; T Johnson; E Hazen; W R Kennedy
Journal:  Pain       Date:  1999-05       Impact factor: 6.961

6.  Estimated prevalence and distribution of reported orofacial pain in the United States.

Authors:  J A Lipton; J A Ship; D Larach-Robinson
Journal:  J Am Dent Assoc       Date:  1993-10       Impact factor: 3.634

Review 7.  The diversity in the vanilloid (TRPV) receptor family of ion channels.

Authors:  Martin J Gunthorpe; Christopher D Benham; Andrew Randall; John B Davis
Journal:  Trends Pharmacol Sci       Date:  2002-04       Impact factor: 14.819

8.  A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia.

Authors:  C P Watson; K L Tyler; D R Bickers; L E Millikan; S Smith; E Coleman
Journal:  Clin Ther       Date:  1993 May-Jun       Impact factor: 3.393

9.  Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control.

Authors:  Laszlo Karai; Dorothy C Brown; Andrew J Mannes; Stephen T Connelly; Jacob Brown; Michael Gandal; Ofer M Wellisch; John K Neubert; Zoltan Olah; Michael J Iadarola
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

10.  Signs and symptoms of first-onset TMD and sociodemographic predictors of its development: the OPPERA prospective cohort study.

Authors:  Gary D Slade; Eric Bair; Joel D Greenspan; Ronald Dubner; Roger B Fillingim; Luda Diatchenko; William Maixner; Charles Knott; Richard Ohrbach
Journal:  J Pain       Date:  2013-12       Impact factor: 5.820

View more
  5 in total

1.  End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain.

Authors:  Ann T Farrell; Julie Panepinto; C Patrick Carroll; Deepika S Darbari; Ankit A Desai; Allison A King; Robert J Adams; Tabitha D Barber; Amanda M Brandow; Michael R DeBaun; Manus J Donahue; Kalpna Gupta; Jane S Hankins; Michelle Kameka; Fenella J Kirkham; Harvey Luksenburg; Shirley Miller; Patricia Ann Oneal; David C Rees; Rosanna Setse; Vivien A Sheehan; John Strouse; Cheryl L Stucky; Ellen M Werner; John C Wood; William T Zempsky
Journal:  Blood Adv       Date:  2019-12-10

2.  Analgesic effects of alcohol in adults with chronic jaw pain.

Authors:  Darya Vitus; Michelle K Williams; Mehdi Rizk; John K Neubert; Michael Robinson; Jeff Boissoneault
Journal:  Alcohol Clin Exp Res       Date:  2022-08-22       Impact factor: 3.928

Review 3.  Fight fire with fire: Neurobiology of capsaicin-induced analgesia for chronic pain.

Authors:  Vipin Arora; James N Campbell; Man-Kyo Chung
Journal:  Pharmacol Ther       Date:  2020-11-10       Impact factor: 12.310

Review 4.  Capsaicin and Gut Microbiota in Health and Disease.

Authors:  Adrian Eugen Rosca; Mara Ioana Iesanu; Carmen Denise Mihaela Zahiu; Suzana Elena Voiculescu; Alexandru Catalin Paslaru; Ana-Maria Zagrean
Journal:  Molecules       Date:  2020-12-02       Impact factor: 4.411

5.  Children and adolescents with sickle cell disease have worse cold and mechanical hypersensitivity during acute painful events.

Authors:  Amanda M Brandow; Karla Hansen; Melodee Nugent; Amy Pan; Julie A Panepinto; Cheryl L Stucky
Journal:  Pain       Date:  2019-02       Impact factor: 7.926

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.